In recognition of the crucial role that clinical research plays in new drug discovery, PhRMA this year established the Clinical Trial Exceptional Service Award, honoring in its first year three individuals who made significant contributions to the development of ZYVOX. The recipients – who “were all instrumental in achieving a scientific breakthrough that has literally helped improve the lives of millions of patients worldwide,” PhRMA’s President and CEO Billy Tauzin said – included:


Donald H. Batts, M.D., Professor of Medicine at Michigan State University College of Human Medicine-Kalamazoo Campus, and Sharon Nachman, M.D., Professor of Pediatrics and Division Chief of Pediatric Infectious Diseases, Stony Brook University Medical Center in New York, two researchers who helped make incredible advances in the clinical trials which were critical to ZYVOX’s development, and Maryam Imam, an 11-year-old volunteer patient who as an infant participated in compassionate use clinical trials of ZYVOX.